Zoetis - Class A opened higher at $79.84, compared with its previous close of $77.75. In the last trading session, the stock traded between $79.22 and $80.40. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Zoetis - Class A is now worth
$ 36.91
resulting in a loss of
$ 63.09 (63.09%)
Note: Past profits do not guarantee future returns.
Rating from 12 Analysts
Today's Change
+$2.04 (+2.62%)
Day High
$80.40
Day Low
$79.22
Day Open
$79.84
Prev Close
$77.75
Volume
10,54,797
1W Return
-2.68%
1M Return
13.50%
3M Return
2.40%
6M Return
-29.91%
1Y Return
-44.57%
Market Cap ($ Mn)
32,971
PE Ratio
12.72
PB Ratio
10.17
PEG Ratio
1.45
ROE
57.78%
ROCE
29.45%
EPS (TTM)
$1.67
1 Week
-2.68%
1 Month
13.50%
3 Months
2.40%
6 Months
-29.91%
9 Months
-34.45%
Jefferies downgrades Zoetis to Hold, cuts price target to $83
Jefferies downgraded Zoetis from Buy to Hold. Price target lowered from $103 to $83. Analyst Keith Devas issued the revised rating.
10 days agoZoetis Q2FY26 Results: Organic revenue falls 1%, full-year outlook cut
Organic revenue declined 1% to $2.5 billion, with adjusted net income down 2% to $781 million. US Companion Animal revenue fell 11%, driven by lower clinic visits and intense competition in dermatology and parasiticides. Livestock segment grew 11% globally, with US Livestock surging 23% due to screwworm-related demand and cattle strength. Full-year organic revenue guidance revised to a decline of 3% to 1%, reflecting persistent market pressures. Leadership reshuffle announced with Jay Zakara joining as CFO and COO to drive operational efficiency.
24 days agoZoetis sets Nov 5 webcast for Q3FY26 earnings review
Zoetis schedules Q3FY26 earnings call for November 5, 2026. CEO Kristin Peck and CFO Jay Saccaro to lead presentation. Webcast accessible via Zoetis investor relations portal.
1mo agoZoetis CEO and CFO to speak at Morgan Stanley healthcare conference
Zoetis Inc. (NYSE: ZTS) executives will speak at the Morgan Stanley 24th Annual Global Healthcare Conference. CEO Kristin Peck and CFO Jay Saccaro are scheduled for a fireside chat on September 14, 2026. The session will begin at 1:50 pm ET and will be available via live audio webcast. A replay of the presentation will be posted on the Zoetis investor website after the event.
1mo agoZoetis secures FDA emergency use authorization for Simparica Trio against screwworm
Zoetis Inc. secured FDA Emergency Use Authorization for Simparica Trio to treat New World screwworm in dogs, expanding its multi-species defense strategy. The company also utilizes Dectomax-CA1 Injectable for livestock protection under conditional approval and separate EUAs. These measures address growing state-level mandates for animal treatment in infested regions.
2mo agoWilliam Blair downgrades Zoetis to Market Perform
William Blair analyst Brandon Vazquez downgrades Zoetis (NYSE: ZTS) from Outperform to Market Perform. This rating change indicates a neutral outlook for the stock, suggesting it will perform in line with the market rather than outperforming peers.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $1,373.70 | +6.63% | $12,93,142.11M | 39.43 | |
| $275.20 | +1.53% | $6,62,491.71M | 31.06 | |
| $290.79 | +1.68% | $5,13,859.95M | 72.17 | |
| $146.33 | +3.83% | $3,61,021.28M | 117.74 | |
| $161.10 | +3.22% | $3,27,809.50M | 23.23 | |
| $174.40 | +2.88% | $2,70,478.36M | 24.32 | |
| $460.73 | +1.97% | $2,49,085.38M | 26.86 | |
| $165.61 | +4.03% | $2,05,348.95M | - | |
| $29.95 | +1.70% | $1,70,705.24M | 36.79 | |
| $39.14 | +2.22% | $1,32,689.61M | 11.15 | |
| $61.39 | +1.35% | $1,25,402.27M | 14.67 | |
| $48.68 | -0.12% | $1,05,059.03M | 16.01 |
An investment of $100 made 5 years ago in Zoetis - Class A is now worth
$ 36.91
resulting in a loss of
$ 63.09 (63.09%)
Note: Past profits do not guarantee future returns.
